Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors
Clinical trial NCT04328831 · COMPLETED
Trial details
- NCT number
- NCT04328831
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-31
- Primary completion
- 2023-08-28
- Enrollment
- 94
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.